S3 Table – Selection of 15 analytes; Sensitivity and specificity as serum markers

		43 HRN cases and 87 controls			28 TN cases and 87 controls		
	Selection Criterion	**Sensitivity at 100% specificity**	**Sensitivity at 95% specificity**	**Sensitivity at 90% specificity**	**Sensitivity at 100% specificity**	**Sensitivity at 95% specificity**	**Sensitivity at 90% specificity**
CA125	1	2.3%	11.6%	14.0%	3.6%	14.3%	14.3%
GDF15	1	4.7%	11.6%	14.0%	3.6%	10.7%	14.3%
PKM	1	0.0%	0.0%	17.5%	0.0%	0.0%	24.0%
SPARC	1	2.3%	7.0%	14.0%	0.0%	3.6%	10.7%
WFDC2	1	4.7%	9.3%	11.6%	7.1%	10.7%	14.3%
COL1A1	2	0.0%	2.3%	2.3%	0.0%	0.0%	0.0%
CTGF	2	7.0%	7.0%	9.3%	7.1%	7.1%	7.1%
FN1	2	0.0%	11.6%	18.6%	0.0%	7.1%	17.9%
S100A7	2	0.0%	2.3%	16.3%	0.0%	0.0%	14.3%
SPP1	2	10.0%	10.0%	15.0%	12.0%	12.0%	16.0%
CCL5	3	2.4%	12.2%	24.4%	0.0%	11.5%	23.1%
miR-135b	3	0.0%	0.0%	4.7%	0.0%	0.0%	3.6%
Anti-TP53	3	4.7%	25.6%	34.9%	3.6%	28.6%	35.7%
HOXA5	4	2.3%	11.6%	11.6%	0.0%	10.7%	10.7%
SFRP1	4	0.0%	7.0%	11.6%	0.0%	7.1%	7.1%

Data from 43 cases and 87 controls. Marker selection criteria: (1) serum marker potential in high-grade serous ovarian cancer and involvement in breast cancer; (2) transcript involved in breast cancer; (3) association with poor breast cancer outcome; (4) protein decreased in breast cancer tissue compared to normal breast. Changes in the TN subset relative to the full HRN set are indicated with color shading (green=better, red=worse).